

Ofir Wolach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6540580/publications.pdf>

Version: 2024-02-01

86
papers

1,813
citations

430874

18
h-index

289244

40
g-index

87
all docs

87
docs citations

87
times ranked

3091
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. <i>Annals of Hematology</i> , 2022, 101, 379-387.	1.8	14
2	Casting a NET on cancer: the multiple roles for neutrophil extracellular traps in cancer. <i>Current Opinion in Hematology</i> , 2022, 29, 53-62.	2.5	8
3	Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. <i>Clinical Microbiology and Infection</i> , 2022, 28, 303.e1-303.e4.	6.0	15
4	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. <i>Annals of Hematology</i> , 2022, 101, 581-593.	1.8	4
5	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846.	5.2	8
6	Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. <i>Leukemia Research</i> , 2022, 113, 106773.	0.8	3
7	Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 119.	3.7	10
8	Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. <i>Annals of Hematology</i> , 2022, 101, 1719-1726.	1.8	14
9	Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease. <i>Acta Haematologica</i> , 2021, 144, 229-235.	1.4	0
10	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. <i>Bone Marrow Transplantation</i> , 2021, 56, 1031-1037.	2.4	25
11	Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. <i>European Journal of Haematology</i> , 2021, 106, 64-71.	2.2	3
12	From the Editor's Desk: Publishing in Times of a Pandemic. <i>Acta Haematologica</i> , 2021, 144, 473-475.	1.4	0
13	Diarrheal Morbidity During Hematopoietic Cell Transplantation: The Diagnostic Yield of Stool Cultures. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1023-1032.	4.0	4
14	Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. <i>American Journal of Hematology</i> , 2021, 96, 790-795.	4.1	20
15	Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients—a multicenter retrospective observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-7.	1.3	2
16	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. <i>Hemato</i> , 2021, 2, 305-328.	0.6	3
17	Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 7007-7007.	1.6	1
18	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2747-2754.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management. <i>Scientific Reports</i> , 2021, 11, 11940.	3.3	3
20	Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity. <i>Leukemia and Lymphoma</i> , 2021, 62, 2921-2927.	1.3	9
21	Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. <i>Acta Oncol</i> , 2021, 60, 1335-1341.	1.8	14
22	Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 – Case Series and Review of the Literature.. <i>European Journal of Haematology</i> , 2021, , .	2.2	1
23	Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 4876-4876.	1.4	1
24	Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study. <i>Blood</i> , 2021, 138, 1273-1273.	1.4	0
25	Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative. <i>Blood</i> , 2021, 138, 2328-2328.	1.4	5
26	Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative. <i>Blood</i> , 2021, 138, 1271-1271.	1.4	2
27	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 3962-3962.	1.4	0
28	Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. <i>Acta Haematologica</i> , 2020, 143, 65-68.	1.4	4
29	Optimal therapeutic strategies for mixed phenotype acute leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 95-102.	2.5	19
30	Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 2939-2945.	1.8	1
31	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. <i>Blood Advances</i> , 2020, 4, 3822-3828.	5.2	5
32	Venetoclax is safe and efficacious in relapsed/refractory AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 2221-2225.	1.3	30
33	Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. <i>Leukemia and Lymphoma</i> , 2020, 61, 2708-2713.	1.3	2
34	Safety and efficacy of blinatumomab: a real world data. <i>Annals of Hematology</i> , 2020, 99, 835-838.	1.8	19
35	Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. <i>Blood</i> , 2020, 136, 26-28.	1.4	2
36	First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study. <i>Blood</i> , 2020, 136, 27-28.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
38	Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
39	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
40	Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27898.	1.5	22
41	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study. <i>Annals of Hematology</i> , 2019, 98, 2711-2717.	1.8	13
42	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study. <i>Annals of Hematology</i> , 2019, 98, 1927-1932.	1.8	56
43	Risk factors for mortality due to <i>Acinetobacter baumannii</i> bacteremia in patients with hematological malignancies—a retrospective study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2787-2792.	1.3	15
44	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e343-e348.	0.4	7
45	Autologous hematopoietic cell transplantation for AML in first remission—a “An abandoned practice or promising approach?”. <i>Seminars in Hematology</i> , 2019, 56, 139-146.	3.4	6
46	Leucocyte adhesion deficiency—A multicentre national experience. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13047.	3.4	54
47	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2662-2662.	1.4	11
48	Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 5899-5899.	1.4	1
49	The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment. <i>Blood</i> , 2019, 134, 5110-5110.	1.4	0
50	Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b. <i>Blood</i> , 2019, 134, 179-179.	1.4	0
51	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	299
52	Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A). <i>Journal of Clinical Immunology</i> , 2018, 38, 193-203.	3.8	4
53	Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 749-754.	6.0	15
54	Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. <i>European Journal of Haematology</i> , 2018, 101, 297-304.	2.2	27

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant <i>Acinetobacter Baumannii</i> (CRAB) Bacteremia. <i>Blood</i> , 2018, 132, 4953-4953.	1.4	0
56	Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia. <i>Blood</i> , 2018, 132, 5788-5788.	1.4	0
57	Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. <i>Current Opinion in Hematology</i> , 2017, 24, 139-145.	2.5	44
58	Current challenges and opportunities in treating adult patients with Philadelphia ϵ negative acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 705-723.	2.5	18
59	Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. <i>British Journal of Cancer</i> , 2017, 117, 353-357.	6.4	38
60	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. <i>Hematological Oncology</i> , 2016, 34, 28-35.	1.7	12
61	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 \hat{A} years of age with Philadelphia ϵ negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , 2016, 91, 793-799.	4.1	14
62	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1977-1979.	1.3	2
63	Autoimmunity and Inflammation in Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2016, 136, 108-117.	1.4	45
64	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. <i>Cancer Discovery</i> , 2016, 6, 368-381.	9.4	215
65	Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. <i>Blood</i> , 2016, 128, 633-633.	1.4	1
66	Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?. <i>Current Opinion in Hematology</i> , 2015, 22, 123-131.	2.5	3
67	Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study. <i>Hematological Oncology</i> , 2015, 33, 42-47.	1.7	8
68	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 685-691.	2.4	3
69	How I treat mixed-phenotype acute leukemia. <i>Blood</i> , 2015, 125, 2477-2485.	1.4	126
70	Blinatumomab for the Treatment of Philadelphia Chromosome ϵ Negative, Precursor B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 4262-4269.	7.0	20
71	Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. <i>Blood</i> , 2015, 126, LBA-4-LBA-4.	1.4	2
72	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , 2015, 126, 1304-1304.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Increased Activity of Cell Membrane-Associated Prothrombinase, Fibrinogen-Like Protein 2, in Peripheral Blood Mononuclear Cells of B-Cell Lymphoma Patients. <i>PLoS ONE</i> , 2014, 9, e109648.	2.5	4
74	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291.	1.4	5
75	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial. <i>American Journal of Hematology</i> , 2014, 89, 243-248.	4.1	16
76	Variable Clinical expressivity of STAT3 Mutation in Hyperimmunoglobulin E Syndrome: Genetic and Clinical Studies of Six Patients. <i>Journal of Clinical Immunology</i> , 2014, 34, 163-170.	3.8	21
77	Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients – a Single Center Experience. <i>Blood</i> , 2014, 124, 2888-2888.	1.4	0
78	Neutropenia after rituximab treatment. <i>Current Opinion in Hematology</i> , 2012, 19, 32-38.	2.5	58
79	Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2012, 87, 472-478.	4.1	118
80	Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2665-2665.	1.4	0
81	Acute Promyelocytic Leukemia with a Smoldering Course Associated with Therapy-Related Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2011, 126, 152-156.	1.4	4
82	Limited PET-CT May Be Adequate for Interim and End of Therapy Response Assessment in Patients with Early Stage Hodgkin and Aggressive Non-Hodgkin Lymphoma - A Retrospective Single Center Study. <i>Blood</i> , 2011, 118, 1562-1562.	1.4	0
83	Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials. <i>Blood</i> , 2011, 118, 2591-2591.	1.4	1
84	Late-Onset Neutropenia After Rituximab Treatment. <i>Medicine (United States)</i> , 2010, 89, 308-318.	1.0	137
85	Ethnic groups and high sensitivity C-reactive protein in Israel. <i>Biomarkers</i> , 2008, 13, 296-306.	1.9	4
86	Lymphoma and Leukemia Cells Possess Fractal Dimensions That Correlate with Their Biological Features. <i>Acta Haematologica</i> , 2008, 119, 142-150.	1.4	104